Biosplice Therapeutics
Latest round
- Series B
Last raised
- Apr 2021
Total raised
- $120M
Investors
- 5
About Biosplice Therapeutics
Founded in 2020 and based in California, US, Biosplice Therapeutics, Inc. (Biosplice), formerly Samumed, LLC operates as a biotechnology company that develops therapeutics based on alternative pre-mRNA splicing for major diseases. In April 2021, the company received USD 120 million from Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others. The company offers small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing a process that enables a messenger RNA (mRNA) to direct the synthesis of different protein variants intended to treat major diseases in osteoarthritis, oncology, and neurology. Biosplice Therapeutics, Inc. plans to accelerate the development and launch of lorecivivint, a Phase 3 program in osteoarthritis.
Who invested in Biosplice Therapeutics
5 investors across 1 round
See all investors in Biosplice Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Apr 15, 2021
Amount
$120M
Investors
Questions about Biosplice Therapeutics
Who invested in Biosplice Therapeutics?
Biosplice Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biosplice Therapeutics raised?
Biosplice Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Biosplice Therapeutics last raise money?
Biosplice Therapeutics's most recent round on record is a Series B, in Apr 2021.
What does Biosplice Therapeutics do?
Founded in 2020 and based in California, US, Biosplice Therapeutics, Inc.
Where is Biosplice Therapeutics headquartered?
Biosplice Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Biosplice Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Biosplice Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Biosplice Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.